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Abstract: Nociceptors with peripheral and central projections express temperature sensitive transient receptor potential 
(TRP) ion channels, also called thermoTRP’s. Chemosensitivity of thermoTRP’s to certain natural compounds eliciting 
pain or exhibiting thermal properties has proven to be a good tool in characterizing these receptors. Capsaicin, a pungent 
chemical in hot peppers, has assisted in the cloning of the first thermoTRP, TRPV1. This discovery initiated the search for 
other receptors encoding the response to a wide range of temperatures encountered by the body. Of these, TRPV1 and 
TRPV2 encode unique modalities of thermal pain when exposed to noxious heat. The ability of TRPA1 to encode noxious 
cold is presently being debated. The role of TRPV1 in peripheral inflammatory pain and central sensitization during 
chronic pain is well known. In addition to endogenous agonists, a wide variety of chemical agonists and antagonists have 
been discovered to activate and inhibit TRPV1. Efforts are underway to determine conditions under which agonist-
mediated desensitization of TRPV1 or inhibition by antagonists can produce analgesia. Also, identification of specific 
second messenger molecules that regulate phosphorylation of TRPV1 has been the focus of intense research, to exploit a 
broader approach to pain treatment. The search for a role of TRPV2 in pain remains dormant due to the lack of suitable 
experimental models. However, progress into TRPA1’s role in pain has received much attention recently. Another ther-
moTRP, TRPM8, encoding for the cool sensation and also expressed in nociceptors, has recently been shown to reduce 
pain via a central mechanism, thus opening a novel strategy for achieving analgesia. The role of other thermoTRP’s 
(TRPV3 and TRPV4) encoding for detection of warm temperatures and expressed in nociceptors cannot be excluded. This 
review will discuss current knowledge on the role of nociceptor thermoTRPs in pain and therapy and describes the activa-
tor and inhibitor molecules known to interact with them and modulate their activity. 
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INTRODUCTION 
  Pain is an unpleasant experience resulting from complex 
and interactive series of mechanisms at multiple levels of the 
nervous system. The afferent pain pathway relays pain sig-
nals from the periphery to the brain via the spinal cord by a 
class of nerve fibers called “nociceptors” [181]. Nociceptors 
(C and A) have peripheral and central terminals originating 
from cell bodies housed in dorsal root ganglia (DRG).   
Peripheral terminals innervate skin and viscera, while   
the central terminals innervate the dorsal horn of the spinal 
cord. Pain perception or nociception is an integration of the 
modulatory events that take place in the periphery (site of 
initial pain), in the dorsal horn (DH) of the spinal cord (pri-
mary processing centers), supraspinal relay centers in brain 
such as the thalamus (secondary processing centers) and the 
corticolimbic structures. Acute and sub chronic pain serves a 
physiological function of warning and withdrawal from 
harmful or noxious stimuli. On the other hand, persistent 
chronic pain associated with inflammatory tissue damage 
and or nerve injury is considered pathological. Pathological 
pain can prolong pain sensation and become maladaptive if 
left unmanaged or untreated. Also, in pathological pain there 
is heightened sensitization of nociceptors due to changes in 
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the milieu that regulates sensory transducers to function to-
wards more damaging pain.  
  A solution to effectively treat pain originating from such 
tissue or nerve damage is to better understand the mecha-
nisms of nociceptive transmission of potential sensory trans-
ducers of pain and their regulation within the nociceptors. 
One such major family of sensory transducers in nociceptors 
belongs to the Transient Receptor Potential (TRP) family of 
cation channels [139, 34]. The uniqueness of these receptors 
is that they render the nociceptors polymodal, responding to 
chemical, thermal and mechanical stimuli. Their unique re-
sponsetotemperaturehas given them the name thermoTRP’s. 
These include members from the subfamily vanilloidTRPV 
(TRPV1, 2, 3 and 4), melastatinTRPM (TRPM8), and an-
kyrin transmembrane proteins TRPA (TRPA1) [45]. Be-
tween them, response to noxious heat is mediated by TRPV1 
and TRPV2, innocuous warm temperature by TRPV3 and 
TRPV4, innocuous cool temperature by TRPM8 and noxious 
cold by TRPA1 [45]. Discovery of thermoTRP’s as molecu-
lar targets for some of the naturally occurring compounds 
that elicit thermal or painful behavior underlies the basis for 
such sensory functions of nociceptors. Much of the past, 
current and future thermoTRP research is based on leads 
obtained from TRPV1, the first cloned thermoTRP member. 
In order to achieve significant analgesia from a state of acute 
or chronic pain following noxious chemical or thermal stim-
uli and tissue damage to nociceptors it is imperative to target 22    Current Neuropharmacology, 2008, Vol. 6, No. 1 Mandadi and Roufogalis 
a range of thermoTRP’s for developing new therapeutic 
strategies.  
  Several lines of evidence ranging from in vitro and in 
vivo studies in animals to humans have proved TRPV1 to be 
a potential target in nociceptors for the treatment of patho-
logical pain, ranging from inflammation to neuropathies. The 
paradigm that TRPV1 can serve as a target for alleviating 
certain pain modalities has generated interest in expanding 
the search for other thermoTRP’s which will also serve as 
targets for pain relief. This review will focus on current re-
search scenarios highlighting the role of thermoTRP’s in 
nociception, with TRPV1 still the front runner in this search. 
Here we discuss selected thermoTRP’s in the sequence 
TRPV1,TRPV2,TRPA1,TRPM8, TRPV3 and lastly TRPV4 
The selected thermoTRP's represent sensitivity to a range of 
temperatures from noxious heat (TRPV1, TRPV2) and cold 
(TRPA1) to innocuous cool (TRPM8) and warmth (TRPV3, 
TRPV4). 
TRPV1  
  A new horizon in pain research was realized in 1997 
when Julius and colleagues [25] identified the specific recep-
tor responding to the hot chilli pepper active ingredient, cap-
saicin, in subsets of nociceptors. The name vanilloid receptor 
1 (VR1) coined by the group is now re-named TRPV1 under 
the unified nomenclature for the family of TRP cation chan-
nels [34,139]. TRPV1 stands out as the first thermally gated 
cation channel to be discovered in nociceptors. TRPV1 
knockout studies gave clear evidence of the importance of 
TRPV1 in thermal hyperalgesia, bladder function, reduced 
fever response and more [23, 24]. Since its cloning, TRPV1 
has emerged as an important transducer in several settings of 
pain and beyond, an update of which is highlighted in the 
following sections. 
Expression, Physiology and Pathology  
  The expression pattern of TRPV1 has been widely stud-
ied and there now is a comprehensive amount of data avail-
able to define not only its localization but also functional 
expression in physiology and disease. Functional expression 
of TRPV1 among sensory neurons includes somatosensory 
ganglia, namely dorsal root ganglia (DRG), trigeminal gan-
glia and jugular ganglia. TRPV1 is also expressed in nodose 
ganglia [146]. While trigeminal ganglia peripheral terminals 
innervate the face and mouth, the DRG projects its periph-
eral terminals to the rest of the body. Jugular ganglia receive 
the glossopharyngeal nerve which innervates the pharynx 
and tongue. Nodose ganglia receive the vagus nerve whose 
peripheral terminals innervate viscera of the thorax and ab-
domen. The majority of these afferents belong to the C and 
A class of nociceptors. Peripheral TRPV1 positive termi-
nals are located in layers of skin epidermis, gastrointestinal 
tract (GI), urinary bladder, airways, cardiovasculature and 
oral cavity [146]. In the spinal cord, while the lamina I of 
DH is innervated by a peptidergic subset of TRPV1 positive 
terminals, lamina II is innervated by non-peptidergic TRPV1 
terminals. In the brain TRPV1 terminals are located in the 
solitary tract nucleus and trigeminal nucleus, which receive 
afferentsignalsviavagal, glossopharyngeal and facial nerves. 
Other areas of the brain with TRPV1 expression have been 
reported. They include the ventral medulla, periaqueductyl 
Table 1.  Distribution of TRPV1, TRPV2, TRPA1, TRPM8, TRPV3 and TRPV4 
ThermoTRP  Neuronal Distribution  Non-Neuronal Distribution 
TRPV1  dorsal root ganglia; trigeminal ganglia; jugular ganglia; nodose 
ganglia; solitary tract nucleus; trigeminal nucleus; ventral me-
dulla; periaqueductyl grey; dorsal raphe nucleus; locus coer-
uleus; 
hypothalamus; thalamus; hippocampus; ventral tegmental area; 
cerebellum; substantia nigra; somatosensory cortex 
epithelial cells of the GI, airway and bladder; epidermal kerati-
nocytes from human skin; enterocytes; liver; vascular endothe-
lium; mast cells; smooth muscle; fibroblasts; peripheral mono-
nuclear blood cells. 
TRPV2  dorsal root ganglia; trigeminal ganglia; nodose ganglia; spinal 
cord Lissauer's tract, dorsal column nuclei, posterior column, 
ventral horn, motoneurons, sympathetic preganglionic neurons, 
central canal ependymal; hypothalamic paraventricular nuclei, 
suprachiasmatic nuclei, supraoptic nuclei, oxytocinergic and 
vasopressinergic neurons; cerebral cortex 
vascular and cardiac myocytes; mast cells; astrocytes; spleen; 
lung; intestine; vas deferens 
TRPA1  dorsal root ganglia; nodose ganglia; trigeminal ganglia; superior 
cervical ganglion; geniculate ganglia 
lung fibroblasts; hair cell stereocilia; intestine; skeletal muscle; 
heart; immune system 
TRPM8  dorsal root ganglia; trigeminal ganglia; nodose ganglia  prostate; urogenital tract; taste papillae; testis; scrotal skin; 
bladder urothelium; thymus; breast; ileum; 
TRPV3  dorsal root ganglia; motor neurons; superior cervical ganglia; 
nigral dopaminergic neurons 
keratinocytes; hair follicle sheath cells; skeletal muscle; pitui-
tary; intestine 
TRPV4  dorsal rrot ganglia; trigeminal ganglia; circumventricular or-
gans; choroids plexus; cerebral cortex; thalamus; hippocampus; 
cerebellum; hypothalamus 
vascular aortic endothelium; blood–brain barrier endothelium; 
renal collecting duct; vascular smooth muscle; cochlea; kerati-
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grey, dorsal raphe nucleus, locus coeruleus, hypothalamus, 
thalamus, ventral tegmental area, substantia nigra, hippocam-
pus, cerebellum and somatosensory cortex [193]. However, 
the physiological function of TRPV1 in these areas is still in 
its infancy with respect to making major claims.  
  The non-neuronal distribution of functional TRPV1 in-
cludes epithelial cells of the GI, airway and bladder; epider-
mal keratinocytes from human skin; enterocytes; liver; vas-
cular endothelium; mast cells; smooth muscle; fibroblasts; 
and peripheral mononuclear blood cells. Despite such a wide 
distribution pattern, nociceptors most abundantly express 
TRPV1, being in the order of more than 30 times that in 
other tissues [25]. Such abundance in nociceptors confers to 
TRPV1 a primary physiological role in transducing pain 
upon its activation by noxious chemical or thermal stimuli 
from the external environment. It also confers a role in medi-
ating pathological pain signals resulting from the changing 
expression and or sensitivity of the receptor to the external or 
internal environment during disease.  
  One component of TRPV1-mediated neuronal dysfunc-
tional states of pain originates at peripheral terminals of no-
ciceptors innervating skin and viscera. These include condi-
tionslikeneurogenic and non-neurogenic inflammation (ther-
mal hyperalgesia, hyperesthesia and allodynia), neuropathy 
(trigeminal neuralgia, post-herpetic neuralgia, diabetic neu-
ropathy and nerve injury), cancer pain (mastalgia and bone 
sarcomas), inflammatory joint pain (osteoarthritis), cardiac 
pain ( heart pain, cardial ischemia), bladder diseases (hyper-
reflexia, interstitial colitis and detrusor overreactivity), GI 
diseases (inflammatory bowel, Crohn’s, ulcerative colitis and 
gastro-oesophageal reflux), vulvodynia, lung diseases (chro-
nic cough and particulate matter-induced apoptosis), head-
ache (cluster headache and migraine) [37, 75, 205- 207]. 
  The other component of TRPV1 mediated pain includes 
central sensitization at the spinal level, where nociceptors 
terminate in the superficial DH. Intradermal injection of cap-
saicin results in primary hyperalgesia to heat and mechanical 
stimuli in the vicinity of the injection site [113, 188, 189]. 
This is followed by the development of secondary mechani-
cal hyperalgesia and allodynia in an area surrounding the site 
[113, 216]. Pain due to secondary hyperalgesia and allodynia 
involve sensitization of nociceptive terminals in the dorsal 
horn. Capsaicin stimulates nitric oxide production via ill-
defined mechanisms, which, in turn, initiates the release of 
glutamate from terminals of vanilloid-sensitive nociceptors 
in dorsal horn [177]. Glutamate activates NMDA receptors 
(NMDAR) on neurons of the dorsal horn, including spi-
nothalamic tract cells. During capsaicin-induced hyperalge-
sia, there are enhanced responses (sensitization) to glutamate 
activation of NMDAR [51, 53]. The positive feedback by 
glutamate on vanilloid-sensitive nerve endings in dorsal horn 
facilitates the release of SP [120]. Dorsal horn neurons in-
volved in pain transmission express receptors (NK-1Rs) for 
SP, which is upregulated during inflammatory hyperalgesia 
[129, 179]. NK-1R antagonists prevent the sensitization of 
spinothalamic tract neurons after intradermal capsaicin in-
jection[52].Therefore,NMDAR-and NKR-mediated mecha-
nisms facilitate central sensitization of dorsal horn during 
development of capsaicin-induced hyperalgesia. However, 
mechanisms for TRPV1-mediated thermal hyperalgesia dur-
ing neuropathic pain could not be confirmed, as there was 
increased TRPV1 expression in uninjured neurons [171]. 
Also, tactile allodynia prevails in a neuropathic pain model 
where C nociceptors are ablated by capsaicin, largely due to 
recruitment of de novo TRPV1-positive A afferents for pain 
signalling following central sensitization [171]. The role of 
NMDAR in central sensitization during peripheral hypersen-
sitivity-mediated visceral pain involves a TRPV1-mediated 
component in parallel to mechanisms described for periph-
eral thermal-hyperalgesia [234]. However, a supraspinal 
regulationofthisconditionis also in place, whereby NMDAR 
activation in the rostral ventro-medial medulla maintains the 
central sensitization at the spinal cord via its descending 
modulation. Visceral pain is also regulated by other supra-
spinal areas, like the cortex and hypothalamus, with TRPV1-
positive neurons. These areas control visceral afferent noci-
ceptive processing during diseases associated with emotional 
states like stress and anxiety [193]. A direct or regulatory 
role for TRPV1 in such disease states needs further investi-
gation. 
  In addition to the importance of receptor distribution, two 
other basic rules for heightened TRPV1-mediated pain proc-
essing by the nociceptors can be sensitization and upregula-
tion of expression during disease. An increase in TRPV1 
expression occurs in primary sensory neurons after periph-
eral inflammation and requires retrograde transport of nerve 
growth factor (NGF). NGF pathways of increased TRPV1 
expression include activation of p38 mitogen-activated pro-
tein kinase (MAPK) and phosphoionositide 3 kinase (PI3K) 
and phospholipase C (PLC) [18, 30, 93, 136, 194, 242, 244]. 
Moreover, protein kinase C (PKC) activation induces rapid 
delivery of TRPV1 channels to the cell membrane, contribut-
ing to the sensitizing effect of this kinase on TRPV1 [142]. 
Increases in the trafficking of TRPV1 to the periphery con-
tribute to inflammatory pain hypersensitivity [93], a problem 
that can be easily targeted via therapeutic blocking by 
TRPV1 antagonists. It is the TRPV1 sensitization by a myr-
iad of endogenous activators and modulators that has drawn 
a great deal of attention, aimed at finding a comprehensive 
approach to silencing the receptor during specific modalities 
[170]. Another aspect of TRPV1 is the paradoxical state of 
desensitization following its activation by agonists, whereby 
the desensitized TRPV1 represents analgesia. Thus, while 
newly developed antagonists present a promising avenue to 
block TRPV1-mediated pain, the age old formula of TRPV1 
desensitization by its agonists has not lost its importance. 
The following sections will address these topics.  
Activation and Regulation 
Endogenous Activators  
  A wide variety of endogenous substances that can acti-
vate TRPV1 have been discovered. These include lipids such 
as  N-arachidonoyldopamine (NADA), oleoylethanolamide 
(OEA) and N-oleoyldopamine (NODA) [2, 28, 82, 219] and 
their metabolite anandamide [246], which is also a cannabi-
noid receptor ligand [44].  
  Other lipid mediators include metabolites of the lipoxy-
genase (LOXs) pathway, namely, 12- and 15-(S)-hydroper-24    Current Neuropharmacology, 2008, Vol. 6, No. 1 Mandadi and Roufogalis 
oxyeicosatetraenoic acids (12- and 15-HPETE), 5- and 15-
(S)-hydroxyeicosatetraenoic acids (5- and 15-HETE); leukot-
riene B4 [85, 183] polyamines (spermine). These endoge-
nous ligands contribute to TRPV1-mediated pain in disease 
where the receptor is sensitized via a variety of signaling 
cascades, as described in the next section.  
Sensitization via Signaling Molecules 
 Prostaglandin  E2 (PGE2), bradykinin, NGF, extracellular 
ATP, glutamate, trypsin, prolactin, prokineticin2 (Bv8) are 
pro-inflammatory mediators that activate their respective 
receptors EP prostaglandin, B1/B2 bradykinin, high-affinity 
TrkANGFreceptor, P2Y2, mGlu 5, PAR-2, PRLR and PKR2 
G protein-coupled receptors [48, 96, 148, 221]. Activation of 
these receptors in nociceptors leads to activation of phos-
pholipase C (PLC), phospholipase A2 (PLA2), adenylyl cy-
clase, protein kinase C (PKC) and protein kinase A (PKA) 
signaling pathways. These pathways result in sensitizing 
TRPV1 indirectly via phosphorylation [96]. PLC hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) and hydrolysis 
of PIP2 also releases inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol(DAG),whichactivatePKC,leading to TRPV1 
phosphorylation [83]. Proposed relief of TRPV1 from PIP2 
mediated tonic inhibition [30] is debatable as PIP2 was 
shown to sensitize TRPV1 when applied intracellularly [173, 
194]. Other pathways that potentiate TRPV1 are activation 
by PI3K [244] either via calmodulin-dependent kinase II 
(CaMKII), PKC, or ERK [244] or PKA [185]. The PLA2
pathway produces arachidonic acid (AA), which can be con-
verted to 12-hydroperoxyeicosatetraenoic acid (12-HPETE) 
by 12-lipoxygenase (LOX). HPETE activates TRPV1 [183]. 
Inhibition of PLC, PKC, PLA2, and PKA reduce peripheral 
nociception [61, 79]. Sensitization of TRPV1 via a multitude 
of signaling cascades during disease poses a challenge to 
therapy with agonists, while antagonists would prove more 
beneficial. Pros and cons of potential agonists and antago-
nists in therapy are discussed in sections below.
Mechanisms of Desensitization- the Paradox with Activa-
tion 
  TRPV1 can be desensitized following its activation and 
desensitization is calcium and phosphorylation-state depend-
ent [212]. Prolonged or repeated application of capsaicin 
induces a desensitization of TRPV1, representing analgesia, 
a paradox in pain biology.  The calcium dependence of 
TRPV1 desensitization was reproduced in a non-neuronal 
context, where desensitization of TRPV1 expressed in Xeno-
pus oocytes required the presence of extracellular calcium 
[25]. Capsaicin-induced desensitization is a complex process 
with varying kinetic components. A fast component appears 
to be dependent on intracellular calcium, voltage, and cal-
cineurin activity, while a slower component appears at least 
to be ATP dependent [49, 110, 167, 215]. Further complexity 
is overlaid by interactions between factors such as voltage-
dependent calcium influx and calcium-dependent phospha-
tase activity [151, 138, 163]. Recently, advances have been 
made at the molecular and biochemical level to understand 
how phosphorylation by protein kinases regulates TRPV1 
desensitization. 
  The cAMP-dependent PKA signal pathway decreases 
desensitization of TRPV1 wild type. Disruption of phos-
phorylation at potential PKA phosphorylation site S116D 
(replacing serine (S) residue with alanine (A)) [16, 137] pre-
vented desensitization. Unlike PKA-dependent reversal of 
TRPV1 tachyphylaxis by short repeated applications of cap-
saicin, acute desensitization of wild type (WT) TRPV1
evoked by a prolonged capsaicin application remained unaf-
fected by PKA. 
Table 2. Ligands for TRPV1, TRPV2, TRPA1, TRPM8, TRPV3 and TRPV4 
ThermoTRP Non-endogenous  Endogenous 
TRPV1  vanilloids (capsaicin, resiniferatoxin, piperine, eugenol, gin-
gerols, capsiate, NGX-4010, WL-1002); non-vanilloids (ginse-
nosides, cannabidiol, evodia compounds, unsaturated 1,4-
dialdehyde terpenes, triprenyl phenol, polygodial and drimanial, 
unsaturated 1,4-dialdehyde sesquiterpenes, 2-APB, camphor) 
N-arachidonoyldopamine (NADA); oleoylethanolamide (OEA); 
N-oleoyldopamine (NODA); anandamide; 12- and 15-(S)-
hydroperoxyeicosatetraenoic acids (12- and 15-HPETE), 5- and 
15-(S)-hydroxyeicosatetraenoic acids (5- and 15-HETE); leu-
kotriene B4; polyamines (spermine) 
TRPV2 2-APB   
TRPA1  isothiocyanates; cinnamaldehyde; THC; acrolein; eugenol; 
methyl salicylate; icilin; gingerol; URB597 
calcium 
TRPM8  terpenes (menthol, eucalyptol, Menthone, geraniol, linalool, 
menthyl lactate, trans- and cis-p-menthane-3,8-diol, isopulegol, 
hydroxy-citronellal); non-terpenes (Icilin (AG-3–5), WS23, 
WS3, Frescolat ML, Frescolat MGA, Cooling-agent 10) 
lysophospholipids 
TRPV3  carvacrol; thymol; eugenol; 6-tert-butyl-m-cresol; dihydro-
carveol; carveol; (+)-borneol; camphor; menthol; 2-APB; 
diphenylboronic anhydride (DPBA); cinnamaldehyde 
TRPV4  synthetic phorbol esters; bisandrographolide A (BAA)  anandamide (AEA); arachidonic acid (AA); epoxyeicosatrienoic 
acid (EET) metabolites (5,6-EET; 8,9-EET; 11,12-EET); N-acyl 
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  Mutation of a single amino acid in transmembrane do-
main 6 (TM6) of TRPV1, Y671K or Y671R (replace tyro-
sine (Y) with lysine (K) or arginine (R)), dramatically altered 
the high relative Ca
2+ permeability and desensitization prop-
erties of the receptor [137]. Both mutations Y671K and 
Y671R showed a decrease in relative permeability for Ca
2+
over Na
+ ions and the mutated receptor did not desensitize at 
all.  
  Interestingly, calcium entry following capsaicin applica-
tion is found to form a CaM/Ca
2+ complex with a 35-aa seg-
ment of TRPV1 and cause desensitization [154]. This was 
confirmed by disrupting of a 35-aa segment in TRPV1, 
which inhibited capsaicin-induced tachyphylaxis and acute 
desensitization [154]. 
  Reversal of TRPV1 desensitization as a positive feed-
back-loop for regaining activity was shown to be mediated 
by CaMKII or PKC [97, 127, 128]. Mutation of TRPV1 at 
the CaMKII consensus sites of TRPV1 phosphorylation 
S502 or T704 showed lack of agonist binding. Recovery of 
the sensitivity of desensitized TRPV1 was achieved via
PKC mediated phosphorylation at S800 residue [128]. 
  Current knowledge points to the conclusion that phos-
phorylated TRPV1 is active and sensitized, while its de-
phosphorylated state represents desensitization. Phosphoryla-
tion of TRPV1 by kinases appears to be critical for its sensi-
tization, and dephosphorylation by calcineurin appears to be 
critical for its desensitization. However, further work is still 
needed to identify the site of de-phosphorylation that deter-
mines inactivation of TRPV1. This will make available the 
molecular determinant that can overcome the influence of 
the milieu of modulators that can sensitize TRPV1 via phos-
phorylation in disease. These models can be applied to spe-
cific disease states that can alter the milieu of relevant sec-
ond messenger systems.  
Therapeutic Potential- Agonists Versus Antagonists 
  This section describes compounds that have been con-
firmed as TRPV1 agonists or antagonists following the clon-
ing of the receptor, in addition to traditional use of some in 
pain therapy. Other pharmacological effects in addition to 
TRPV1-mediated mechanisms are not described here. How-
ever, some compounds acting as agonists or antagonists for 
other thermoTRP’s are included. 
Vanilloids 
  TRPV1 had derived its maiden name Vanilloid Receptor 
subtype 1 (VR1) [25] from the fact that it was cloned with 
the help of capsaicin (trans-8-methyl-N-vanillyl-6-nonena-
mide), which belongs to the vanilloid class of compounds 
composed of the vanillyl moiety in their chemical structure. 
Capsaicin to date has been shown to selectively activate 
TRPV1, thus making it one of the most prolifically used spe-
cific pharmacological tools in pain research. Much earlier to 
the cloning of TRPV1, the hallmark agonist capsaicin has 
been traditionally in use for pain relief of peripheral origin in 
different disease settings like chemical or thermal hyperalge-
sia in neurogenic inflammation, herpes zoster, neuropathy, 
paresthetica, thoracotomy, mastectomy, amputation, and skin 
cancer [37, 64, 75, 206, 209]. Other disease states of visceral 
origin that have found capsaicin useful are bladder detrusor 
instability, hyperreflexia and migraine. Resiniferatoxin, a 
phorbol ester with the vanillyl moiety, is an ultrapotent ago-
nist of TRPV1 and has also been under intense clinical trial 
evaluation for relieving incontinence [38, 187]. Alkaloid 
piperine (piperinoyl-piperidine), the pungent ingredient of 
black or white pepper, reduces intestinal motility in vivo in 
mice by a mechanism that seems to involve capsaicin-
sensitive neurons [91]. Eugenol, a phenol with vanillyl moi-
ety is derived from clove oil and cinnamon leaf oil [59] and 
used for toothache, pulpitis, and dentin hyperalgesia [157, 
158]. However, eugenol is a nonselective TRPV1 agonist as 
it is also activates other thermoTRP’s, namely TRPA1 and 
TRPM8 [11]. The other class of phenol compounds with 
vanillyl moiety that are derived from ginger include gin-
gerols ([8]-gingerol and [6]-gingerol) used in traditional 
Chinese medicine for headaches, nausea, colds, arthritis, 
rheumatological disorders and muscular discomfort [43, 
175]. Gingerols also activate TRPA1 [11]. In addition to 
gingerols, [6]-shogaol [59] is also used for its analgesic 
properties. Other less effective compounds that are TRPV1 
agonists include zingerone, a phenolic ketone metabolite of 
gingerols, and Capsiate (4-hydroxy-3-methoxybenzyl (E)-8-
methyl-6-nonenoate) obtained from a non-pungent cultivar 
of red peppers (as C. annuum or C. frutescens), named CH-
19 Sweet [88, 104]. Typical routes of administration for va-
nilloids include topical, visceral instillations, injections to 
epidural or subarachnoid space in the case of deep tissue 
pain, perineural route in neurogenic inflammation. Such 
treatment regimens mainly include reversible and or irre-
versible loss of capsaicin-sensitive C-fibers as a mechanism 
for analgesic effect. Pungency and irritation of vanilloid 
compounds have been the major drawbacks in pain therapy. 
However, synthetic analogs of some of the naturally occur-
ring vanilloids have been developed to overcome the pun-
gency factor, such as NGX-4010 (NeurogesX), which is in 
phase III trials for postherpetic neuropathy, HIV-associated 
sensory neuropathy; WL-1002 (Winston Laboratories) is 
under clinical trial for cluster headache, migraine and os-
teoarthritic pain; compound 4975 (Anesiva) is under clinical 
trial for neuropathic and musculoskeletal pain. 
Non-vanillyl Compounds  
  The list of TRPV1 agonists has increased several fold in 
recent years, to include non-vanillyl naturally occurring 
agents, some of which are partial antagonists such as the 
Ginseng derivatives ginsenosides [21]; Cannabidiol, a can-
nabinoid [133]; Evodia compounds (evodiamine and rutae-
carpine), alkaloids from Evodia rutaecarpa fruits [78, 106-
109, 164]; unsaturated 1,4-dialdehyde terpenes [196]; tripre-
nyl phenol (scutigeral), from Albatrellus ovinus [74, 208]; 
jellyfish and cnidarian envenomations [41]; spider toxins 
[95] and polygodial and drimanial, unsaturated 1,4-dial-
dehyde sesquiterpenes isolated from the bark of Drymis win-
teri [9]. However, additional studies are necessary to confirm 
the precise nociceptive or anti-nociceptive mechanism/s 
through which some of these compounds interact or modu-
late the TRPV1 channel.  
TRPV1 Antagonists 
  Since agonists are able to activate nociceptors and cause 
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therapies a difficult choice, specific antagonists of TRPV1 
have been developed, with the aim to overcome the initial 
pain factor associated with using agonists. Capsazepine, a 
first generation TRPV1 antagonist, has been shown to be less 
promising than expected due to its poor pharmacokinetics 
[218].Inadditionto this capsazepine has shown non-selective 
blockade of other ion channels such as voltage-sensitive cal-
cium channels [153], nicotinic acetylcholine receptors [121] 
and TRPM8 [14]. Several pharmaceutical companies like 
GlaxoSmithKline, Novartis, Astra Zeneca, Amgen, Johnson 
& Johnson, Neurogen/Merck, Renovis/Pfizer and so on have 
launched attempts to develop second generation TRPV1 an-
tagonists and some of their concerted efforts are beginning to 
bear fruit as clinical trials are in progress. A number of these 
have been developed, including iodo-RTX, SB705498, 
SB366791, BCTC, NGD-8243, AMG-517, AMG-9810, A-
425619, KJM429, JYL1421, JNJ17203212, NGX-4010, 
WL-1001, WL-1002, A-4975, and GRC-6127. Some of these 
have reached Phase I and or Phase II clinical trials.  
  SB-705498 (GlaxoSmithKline) [169] successfully com-
pleted Phase I clinical trials, whereby it reduced capsaicin-
evoked flare and heat-evoked pain in non-sensitized skin. 
UVB-evoked inflammation was also reduced by SB705498. 
Presently, Phase II trials for the acute treatment of dental 
pain and migraine is underway (ClinicalTrials.gov identifier: 
NCT00269022). A-425619 (Abbott) [1-isoquinolin-5-yl-3-
(4-trifluoromethyl-benzyl)-urea] inhibited mechanical allo-
dynia induced by skin incision and reversed mechanical hy-
peralgesia in rat models of chronic and neuropathic pain [56, 
77]. AMG-9810 (Amgen) [(E)-3-(4-t-Butylphenyl)-N-(2, 3-
dihydrobenzo[b] and dioxin-6-yl) acrylamide] reverted ther-
mal and mechanical hyperalgesia induced by complete Fre-
und'sadjuvant(CFA) [66]. BCTC [N-(4-tertiarybutylphenyl)-
4-(3-cholorphyridin-2-yl)tetrahydropryazine-1(2H)-carbox-
amide] and Nrgn (Neurogen) significantly attenuated thermal 
and mechanical hyperalgesia in the chronic constriction in-
jury (CCI) model of neuropathic pain and CFA model of 
inflammatory pain in rats [111]. GRC 6127 (Glenmark), an 
orally active antagonist, can reverse both CFA-induced and 
partial sciatic-nerve legation-induced mechanical hyperalge-
sia in the rat [111]. JNJ-17203212 (Johnson&Johnson) re-
lieved osteolytic sarcoma-related bone pain in the mouse 
[205]. Similar to capsazepine and iodo-RTX, JNJ-17203212 
can block citric-acid-induced cough in guinea pigs [205]. 
Other recent literature reports on TRPV1 antagonists include 
2-(4-pyridin-2-ylpiperazin-1-yl)-1H-benzo[d]imidazole com-
pound 46ad [156]; 6-aryl-7-isopropylquinazolinones [40]; 
5,6-fused heteroaromatic urea A-425619.0 [55]; 4-amino-
quinazoline [243]; halogenated thiourea compounds 23c and
31b [98]; N-tetrahydroquinolinyl,  N-quinolinyl and N-iso-
quinolinyl carboxamides [233]; pentacyclic triterpene and 
oleanolic acid [125]. 
  Despite these promising developments, TRPV1 antago-
nists are beset with problems of side-effects, largely arising 
from interference with the physiological function of TRPV1-
expressing cells. Recent evidence has shown that orally ac-
tive TRPV1 antagonists can induce gastric ulcer formation, 
hypertension, hyperthermia and central nervous system ef-
fects [76, 207]. It remains to be seen in clinical trials whether 
or not the TRPV1 antagonists have favorable therapeutic 
actions. Some patients on TRPV1 antagonists for pain might 
be at risk of the possible masking of ischemic pain of cardiac 
origin, as C-fibers innervating the heart are blocked [162]. 
Thus TRPV1-ligand effects can be unpredictable in patients 
with complex cardiovascular problems. At present, it is un-
clear to what degree these findings apply to humans. Also, 
TRPV1 antagonists which cross the blood brain barrier may 
cause CNS side effects. 
  In addition to the use of agonists or antagonists, sub-
stances able to modulate TRPV1 (such as at phosphorylation 
sites) or to decrease the production of endogenous ligands 
could also be drugs of clear interest. However, clinical stud-
ies with these modulators are still lacking and such studies 
are critical to demonstrate the efficacy of such molecules in 
controlling certain pain disorders. While from the above dis-
cussion the clinical value of modulation of the first ther-
moTRP member TRPV1 as a target in some pain settings is 
clear, other thermoTRP members have also drawn recent 
attention.  
TRPV2 
  Residual noxious heat sensation at temperatures above 
52
oC in TRPV1 knockout mice led to the discovery of the 
second thermoTRP, originally known as vanilloid receptor 
like protein 1 (VRL-1) and now renamed TRPV2 [22, 140]. 
Since its cloning TRPV2 has emerged as an ion channel with 
distribution and functions not only in nociceptors but also in 
other tissues. 
Expression, Physiology and Pathology  
  TRPV2 is localized in medium to large diameter DRG, 
Trigeminal ganglia and Nodose ganglia neurons representing 
Table 3.  Cell Signaling Modulators of TRPV1, TRPV2, TRPA1, TRPM8, TRPV3 and TRPV4 
ThermoTRP  +ve Modulators  -ve Modulators 
TRPV1  PKC, PKA, CAMKII, ERK, PI3K  calcineurin, calmodulin; PIP2 
TRPV2  IGF-I; AKAP/cAMP/PKA; PI3K; CAMK   
TRPA1  p38 MAPK; ERK; PLC; Artemin  pyrophosphate (PPi); polytriphosphate (PPPi) 
TRPM8 PIP2;  calcium  PKC;  PKA 
TRPV3  arachidonic acid and metabolites; PKC   
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the A and A nociceptors. TRPV2 distribution in spinal 
cord include Lissauer's tract and laminae I, II, III and IV of 
the DH, dorsal column nuclei, posterior column, ventral horn 
of sections at the lumbosacral junction, ventral horn moto-
neurons, intermediolateral (IML) cell column composed of 
sympathetic preganglionic neurons, ependymal cells lining 
the central canal and astrocytes [3, 22, 87, 115, 241]. Central 
projections of A nociceptors with TRPV2 in laminae I and 
II may be involved in nociception, although direct in vivo
evidence is still lacking. However, it is known that TRPV2 
expression in trkC subpopulations of adult DRG’s is depend-
ent on NT-3 signaling in development stages [211]. Since 
NT-3 is reported to induce mechanical and thermal hyperal-
gesia followed by mechanical hypoalgesia [126, 184], it is 
suggested that TRPV2 may play a role in NT-3 mediated 
thermal hyperalgesia. TRPV2 may also serve non-nocicep-
tive functions. Laminae III and IV, dorsal column nuclei and 
posterior column, receive large diameter mechano-A sen-
sory fibers involved in proprioception. TRPV2 in the lumbo-
sacral junction may have a functional role towards the ure-
thral sphincter and ischiocavernosus muscles that are inner-
vated by neurons of the dorsolateral nucleus [131, 180]. A 
role of TRPV2 in CSF transport of molecules is speculated 
due to its presence in the central canal ependymal cells. The 
presence of TRPV2 in NG (vagal afferents) and intrinsic 
neurons of myentric plexus suggest a role for receiving sen-
sory signals from viscera and intestine [86, 100]. Among the 
viscera, laryngeal innervation is TRPV2 positive and hence 
suggests a possible role in laryngeal nociception [159]. In the 
brain, TRPV2 is localized to hypothalamic paraventricular, 
suprachiasmatic, supraoptic nuclei, oxytocinergic and vaso-
pressinergic neurons and cerebral cortex [116]. Since these 
areas of the brain have neurohypophysial function and regu-
lation of neuropeptide release in response to changes in os-
molarity, temperature, and synaptic input, TRPV2 may have 
a role in disorders of the hypothalamic-pituitary-adrenal axis, 
such as anxiety, depression, hypertension, and preterm labor 
[226]. In a model of peripheral axotomy, TRPV2 was up-
regulated in postganglionic neurons in lumbar sympathetic 
ganglia but not in the DRG, spinal cord or brainstem, sug-
gesting a role in sympathetically mediated neuropathic pain 
[65].  
  The non-neuronal distribution of TRPV2 includes vascu-
lar and cardiac myocytes [90, 144, 160] and mast cells [197]. 
TRPV2 is activated by membrane stretch, a property relevant 
for its sensory role in the gut. TRPV2 in cardiac muscle may 
be involved in the pathogenesis of dystrophic cardiomyopa-
thy [89] and in mast cells, and may play a role in urticaria 
due to physical stimuli (thermal, osmotic and mechanical). 
Activation by physical stimuli is discussed in the next sec-
tion. A functional role for TRPV2 recently found in human 
peripheral blood cells needs further study [178].  
Activation and Regulation 
 TRPV2  is  activated  in vitro by physical stimuli such as 
heat, osmotic and mechanical stretch [22, 90, 144] and 
chemical stimulus by 2-aminoethoxydiphenyborate (2-APB) 
[80]. Translocation of TRPV2 from intracellular locations to 
plasma membrane required for its activation is regulated by 
insulin-like growth factor-I (IGF-I) [99]; A-kinase anchoring 
proteins (AKAP)/cAMP/protein kinase A (PKA) mediated 
phosphorylation [197]; G-protein coupled receptor ligands 
like neuropeptide head activator (HA) via phosphatidylinosi-
tol 3-kinase (PI3-K) and of the Ca
2+/calmodulin-dependent 
kinase (CAMK) signaling [17]. These regulatory mecha-
nisms that induce membrane localization of TRPV2 seem to 
be important regulation mechanisms for TRPV2 activation. 
Therapeutic Potential 
  Given the distribution pattern of TRPV2 in sensory affer-
ents and their projections, the predicted physiological and 
pathological role in mediating pain makes it an important 
target for certain pain states in addition to TRPV1. However, 
progress into TRPV2 pharmacology, unlike TRPV1 has been 
patchy and requires more investigations to determine its 
niche in pain biology. In vivo evidence for thermal and me-
chanical nociception via TRPV2 is still elusive. 2-APB, the 
only known chemical activator of TRPV2, is non-selective. 
Ruthenium Red (RR) a general blocker of TRPV ion chan-
nels is non-selective antagonist of TRPV2. The lack of spe-
cific tools and knockout animal models has impeded detailed 
investigations into TRPV2 function in physiology and pa-
thology. Future efforts in this direction are awaited.  
TRPA1 
  The ankyrin-repeat transient receptor potential (TRPA) 
channel subfamily has currently a single member named 
TRPA1(previouslycoined p120, ANKTM1 or TRPN1), with 
characteristic long ankyrin repeats in its N-terminus [92, 94, 
139, 199]. A role for TRPA1 in somatosensation is currently 
not without inconsistencies due to variable pain assay meth-
ods. Evidence for TRPA1 as a thermoTRP directly activated 
by noxious cold [11, 199] could not be reproduced by later 
studies using in vivo TRPA1 knockout model or other het-
erologous expression systems [12, 94]. However, another 
independent knockout study showed a cold response role for 
TRPA1 [112]. Nevertheless, sensory transduction of cold-
induced pain by TRPA1 seems to draw attention. Evidence 
for distribution and function in nociceptors makes TRPA1 an 
exciting new therapeutic target to achieve analgesia.  
Expression, Physiology and Pathology 
  TRPA1 and TRPV1 are co-expressed in C and A noci-
ceptors from DRG, nodose ganglia and trigeminal ganglia 
[105, 145, 199], making these transducers of both noxious 
cold and heat-induced pain. TRPA1 is also expressed in 
sympathetic neurons from the superior cervical ganglion 
[191] and neurons of the geniculate ganglia [102], suggesting 
a role in oral sensory transduction. Non-neuronal expression 
of TRPA1 is currently limited to lung fibroblasts (as 
ANKTM1) [92] and hair cell stereocilia [36, 145] where it 
may serve as a mechanotransducer. Other non-neuronal ex-
pression was found at mRNA levels in small intestine, colon, 
skeletal muscle, heart, brain, and immune system. Nocicep-
tive afferents expressing TRPA1 innervate bladder [8], sug-
gesting a role in bladder contraction. Upregulation of TRPA1 
expression is observed in pathological pain models like cold 
hyperalgesia induced by inflammation and nerve damage 
[155]; exaggerated response to cold in uninjured nerves dur-
ing spinal nerve ligation [101]; cold allodynia during spinal 
nerve injury [7]; bradykinin (BK)-induced mechanical hy-
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normal auditory behaviour in TRPA1 knock out studies, its 
role in hearing has been ruled out [12, 112], and hence its 
role in hair cell mechanotransduction remains challenged 
[36]. Further studies are necessary to clearly define pain 
mechanisms mediated via TRPA1. Also, further evaluation 
TRPA1 expression and function using knockout studies are 
required with emphasis on cold- and mechano-transduction 
mechanisms.  
Activation and Regulation 
  Similar to TRPV1, TRPA1 pharmacology has made great 
strides since the receptor was found to respond to pungent 
ingredients from natural products.  
Isothiocyanates 
  TRPA1 can be selectively activated by pungent ingredi-
ents like allyl, benzyl, phenylethyl, isopropyl, and methyl 
isothiocyanate, from wasabi, yellow mustard, Brussels 
sprouts, nasturtium seeds, and capers, respectively [94]. 
However, its involvement in burning pain induced by the 
mustard oil derivative allyl isothiocyanate in variable subsets 
of nociceptors is debated [12, 24, 94, 112].  
Cinnamaldehyde 
  Cinnamaldehyde, the main pungent constituent from cin-
namon oil, activates TRPA1 [11]. Acute burning pain sensa-
tion caused by cinnamaldehyde is suggested to be mediated 
by TRPA1 expressed in nociceptors that project to the 
tongue and skin [11].  

9-tetrahydrocannabinol 
  THC, a cannabinoid, activates TRPA1 and is suggested 
to induce some of its biological effects, like dilation of he-
patic or mesenteric arteries via activation of capsaicin-
sensitive, CGRP-containing perivascular sensory nerve end-
ings innervating the smooth muscle [247]. THC also acti-
vates TRPA1 in trigeminal neurons [94]. Hence, cannabinoid 
mechanisms may play an important role by interacting with 
the TRPA1 component in these nociceptors. 
Acrolein 
  Acrolein (2-propenal), a higly toxic air pollutant in tear 
gas, vehicle exhaust, and smoke from burning vegetation, 
including tobacco products [72, 73] selectively activated 
TRPA1 [12]. Thus biological effects of acrolein, like apnea, 
shortness of breath, cough, airway obstruction, and mucous 
secretion [67] may result from TRPA1 activation in TRPV1- 
and CGRP-positive afferent innervations of airway. Che-
motherapeutic agents like cyclophosphamide and ifosfamide 
for cancer, severe arthritis, multiple sclerosis, and lupus [62, 
149]generateacroleinasametabolite, suggesting that TRPA1 
may be involved in the side effects of such conditions. Stud-
ies using heterologous expression and knockout systems rule 
out acrolein as a TRPV1 agonist [47, 204]. 
Fatty Acid Amide Hydrolase (FAAH) Inhibitor 
 3'-carbamoylbiphenyl-3-yl  cyclohexylcarbamate  (URB 
597), a potent and systemically active inhibitor of FAAH 
(the enzyme responsible for anandamide degradation) was 
recently shown to directly gate TRPA1 and is being pursued 
as an antinociceptive drug [150].
Non-Selective Activators 
  These include eugenol (from clove oil), gingerol (from 
ginger), and methyl salicylate (from Wintergreen oil), syn-
theticAG-3-5 (Icilin) [132, 200], all of which non-selectively 
activate TRPV1 and TRPM8. Allicin, thought to be a non-
selective activator of TRPV1 and TRPA1 [123] is now being 
considered as a selective agonist for TRPA1 [12]. 
Modulators 
  Like TRPV1, hypersensitivity of TRPA1 is coupled to G-
protein mediated BK signaling and contributes to mechano- 
and cold-hyperalgesia [11, 112]. Noguchi and colleagues 
showed that an increase in NGF-induced TRPA1 in nocicep-
tors via p38 MAPK activation was necessary for cold hyper-
algesia [134, 155]. TRPA1 is potentiated by extracellular 
signal-regulated protein kinase (ERK) and PLC disinhibition 
of PIP2 via proteinase activated receptor (PAR)-2 mediated 
activation in models of thermal hyperalgesia and inflamma-
tory pain [42, 103, 135]. These studies provide further in-
sights into TRPA1 signaling. Like the TRPV1, PLC-medi-
ated pathway sensitization of TRPA1 has been shown [132]. 
Activation of Mu and Kappa opioid receptors antagonized 
the stimulant action of icillin on TRPA1 [232], suggesting a 
Table 4.  Antagonists for TRPV1, TRPV2, TRPA1, TRPM8, TRPV3 and TRPV4 
ThermoTRP Antagonists 
TRPV1  capsazepine; ruthenium red; diphenyltetrahydrofuran (DPTHF); iodo-RTX; SB705498; SB366791; BCTC; NGD-8243; AMG-517; 
AMG-9810; A-425619; KJM429; JYL1421; JNJ17203212; NGX-4010; WL-1001; WL-1002; A-4975; GRC-6127; 2-(4-pyridin-2-
ylpiperazin-1-yl)-1H-benzo[d]imidazole compound 46ad; 6-aryl-7-isopropylquinazolinones; 5,6-fused heteroaromatic urea A-
425619.0; 4-aminoquinazoline; halogenated thiourea compounds 23c and 31b; N-tetrahydroquinolinyl, N-quinolinyl and N-
isoquinolinyl carboxamides; pentacyclic triterpene; oleanolic acid; 
TRPV2  ruthenium red; diphenyltetrahydrofuran (DPTHF) 
TRPA1  ruthenium red; camphor; menthol; compoud A and compound B (Abbott Laboratories) 
TRPM8  capsazepine; BCTC; CTPC; SB-452533; 2-APB; URB597; cinnamaldehyde 
TRPV3  ruthenium red; diphenyltetrahydrofuran (DPTHF) 
TRPV4 ruthenium  red ThermoTRP Channels in Nociceptors  Current Neuropharmacology, 2008, Vol. 6, No. 1    29
central mechanism of interaction between opioid receptors 
and TRPA1. Evidence for TRPA1 as a substrate for ubiquiti-
nation by CYLD (an ubiquitin hydrolase and a tumor sup-
pressor gene product) along with wide tissue distribution 
indicates a probable role in cancer [198]. Further studies are 
necessary to identify wider functional TRPA1 protein ex-
pression. Evidence for indirect gating of TRPA1 by cold is 
shown to be regulated by calcium binding domain (EF hand) 
in the N-terminus [50, 245]. Artemin, a glial cell line-derived 
neurotrophic factor (GDNF) protein, was shown to increase 
TRPA1 gene expression in skin and is suggested to mediate 
cold allodynia during inflammation [57]. Most of these sig-
naling mechanisms involving TRPA1 sensitization of pain 
states need to be addressed using TRPA1 knockout studies in 
tandem with TRPV1 knockout models.
Therapeutic Potential 
  Evidence for TRPA1 as a transducer of pain is certainly 
on the rise, making it yet another important target for ther-
apy. The therapeutic potential of TRPA1 for appropriate 
pharmacological treatment of certain pain states needs fur-
ther investigation. Unlike TRPV1, the agonists of TRPA1 
currently are only known to produce pain and hence antago-
nists are a better choice than agonists as analgesics. One re-
cent published work describes identification of potential 
TRPA1 anatagonists using a novel transient expression sys-
tem screening method [27]. Development of these substances 
is an important step for elucidating the role played by 
TRPA1 in painful conditions. Since activation of TRPA1 in 
nociceptors induces pain behaviour, design of specific an-
tagonists seems beneficial. Since other physiological roles of 
TRPA1 are under debate, further research into its pharma-
cology would help in choosing agonists versus antagonist 
drugs. 
TRPM8 
  TRPM8 (Trp-p8 or CMR1), is a channel belonging to the 
TRPM (long or melastatin) subfamily of TRP channels, with 
a characteristic lack of ankyrin repeat domains in the N-
terminus [34, 130, 140, 165, 217]. The channel was cloned 
initially as an upregulated protein in prostate [217]. Later it 
was discovered as a thermoTRP for cool and menthol sensa-
tion by two groups- one used an expression screening strat-
egy (similar to TRPV1 cloning) for a menthol- and cold-
sensitive receptor [130], while the other used genomic DNA 
databases for TRP protein sequences [165]. The threshold for 
TRPM8 activation is about 25 °C, a temperature in the non-
noxious range. Long awaited studies on the role of TRPM8 
in nociceptors using knockout strategies have now been pub-
lished [13, 35, 46]. These studies have shown that TRPM8 
can serve as thermosensor for cold and mediate both cold-
induced nociception as well as analgesia. However, the 
TRPM8 knockout mice retained response to intense cold 
temperatures below 10 
oC, indicating the presence of other 
thermosensors. A study involving mice with double knock-
out of TRPA1 and TRPM8 would perhaps eliminate the en-
tire range of cool to cold temperature sensation. However, 
this remains to be seen as, Koltzenburg and colleagues have 
shown the presence of a third population of cold-sensitive 
neurons distinct from the TRPA1 and TRPM8 population 
[143].
Expression, Physiology and Pathology 
  Interestingly, TRPM8 is expressed in a subset of sensory 
neurons of C and A class in DRG, trigeminal ganglia and 
nodose ganglia that are negative for nociceptor markers 
TRPV1, CGRP and IB4 [130, 147, 165, 172]. A recent strat-
egy to generate transgenic mice with GFP under the control 
of TRPM8 promotor has good potential to study distribution 
and function in its physiology and pathology [210]. Neuronal 
expression and knockout studies implicate TRPM8 for a so-
matosensory role in cool temperature sensation [13, 35, 46, 
130, 165]. It is believed that TRPM8 activation leads to an-
algesia during neuropathic pain. Evidence for such an anal-
gesic mechanism was recently shown to be centrally medi-
ated, whereby TRPM8-induced glutamate release activates 
inhibitory Group II/III metabotropic glutamate receptors 
(mGluRs) to block nociceptive inputs [168]. However, a role 
for TRPM8 in innocuous cold nociception has also been 
shown [69, 227]. The TRPM8 knockout mice studies more 
clearly point towards a role for TRPM8 in sensory neurons 
in physiological (somatosensation) and pathological condi-
tions (cold pain), especially owing to their presence in C and 
A fibers, generally regarded as nociceptors [13, 35, 46].  
  The non-neuronal expression of TRPM8 is currently re-
stricted to prostate, urogenital tract, taste papillae, testis, 
scrotal skin, bladderurothelium, thymus, breast, ileum and in
melanoma, colorectal cancer and breast cancer cells [1, 195, 
217, 240, 241]. The physiology of TRPM8 in non-neuronal 
tissues is well described elsewhere [240].  
Activation and Regulation 
  TRPM8 pharmacology has also progressed considerably 
due to availability of a number of agonists and antagonists. 
Several studies have also been conducted to understand regu-
latory mechanisms of the receptor.  
Terpenes 
  Menthol, derived from peppermint oil, cornmint oil, cit-
ronella oil, eucalyptus oil, and Indian turpentine oil, activates 
TRPM8 in sensory neurons of DRG and TG [130, 165]. 
Menthol sensitizes TRPM8 to cold stimulus [172]. However, 
menthol is now known to non-selectively activate and sensi-
tize TRPV3 [124]. Eucalyptol derived from Eucalyptus 
polybractea activates TRPM8 with lower efficacy than men-
thol. It is used in as an analgesic for inflammatory and mus-
cular pain [20]. 
  Menthone, geraniol, linalool, menthyl lactate, trans- and 
cis-p-menthane-3,8-diol, isopulegol, and hydroxy-citronellal 
are other terpene compounds known to activate TRPM8 [11, 
14] by mechanisms that need further analysis.  
Non-Terpenes 
  Icilin (AG-3–5), WS23, WS3, Frescolat ML, Frescolat 
MGA, and Cooling-agent 10 are some of the non-terpene 
compounds that have been shown to effectively activate and 
desensitize TRPM8 [20].
Antagonists 
 Non-selectiveantagonistsofTRPM8 include capsazepine, 
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pyrazine-1 (2H)-carboxamide (BCTC) and a thio-derivative 
of BCTC, (2R)-4-(3-chloro-2 pyridinyl)-2-methyl-N-[4-(tri-
fluoromethyl)phenyl]-1 piperazonecarboxamide (CTPC) and 
SB-452533 [14, 231]. Surprisingly, 2-APB, an activator of 
TRPV1, 2 and 3 is an antagonist of TRPM8 [80]. 2-APB 
could be useful in characterizing TRPM8 mechanisms selec-
tively.Agonistsof TRPA1 like cinnamaldehyde and URB597 
are shown to antagonize TRPM8 [124, 150].  
Modulators 
  Voltage dependence of TRPM8 during cold and menthol 
activation suggests its dependence on membrane potential 
for activation [19, 84, 213]. PIP2 was shown to be essential 
for activation of TRPM8, and PIP2 depletion via PLC path-
way activation resulted in desensitization [15, 119, 174]. 
Activation of TRPM8 by icilin was shown to be dependent 
on intracellular calcium [29]. Calcium-independent and 
iPLA2-dependent activation of prostate TRPM8 by lys-
ophospholipids (metabolites of iPLA2) provides a first evi-
dence for endogenous ligands in non-neuronal tissue not 
exposed to cooling [220]. This mechanism has not been at-
tributed to sensory transduction by TRPM8. A structural 
component necessary for formation and trafficking of func-
tional TRPM8 to plasma membrane lies in the coiled-coil C-
terminal region [58]. Other structural motifs necessary for 
channel activation are two cysteine residues in the pore re-
gion flanked by the glycosylation site [54]. Such studies are 
useful to understand the channel function in response to spe-
cific modalities, where TRPM8, like other thermoTRP’s, is 
polymodal. 
  Since TRPM8 activation can mediate both pain and anal-
gesia, it is necessary to develop both agonists and antago-
nists, as seen in the case of TRPV1 for pain management.  
Therapeutic Potential 
  As is the case of TRPA1, therapeutic potential of TRPM8 
with existing data makes it a target to achieve analgesia dur-
ing cold pain. Unlike TRPA1, either activation or blockade 
of TRPM8 is therapeutically useful depending on the mo-
dalities of different pain settings. TRPM8 can also be an 
important target for identification and or therapy of cancer in 
prostate, breast, colon, lung and skin. 
TRPV3 
  TRPV3 is the other thermoTRP that responds to innocu-
ous temperatures with a threshold higher than TRPV4 [166, 
190]. Expression of TRPV3 among sensory neurons is vari-
able between species and thus its role in somatosensation 
needs further investigations [166, 190, 239]. However, an 
increase in TRPV3 expression in peripheral nerves after in-
jury and in avulsed DRG is documented [60]. Evidence for a 
role of TRPV3 in thermosensation has emerged with demon-
stration of its presence in the keratinocytes [31, 32, 166, 239] 
and aberrant thermal selectivity in TRPV3 knockout study 
[141]. In addition, gene knock out studies have shown hair 
loss [10]. CNS expression of TRPV3 includes ventral motor 
neurons, deeper laminae of DH, superior cervical ganglion 
neurons, nigral dopaminergic neurons [70, 60, 190, 239]. A 
physiological role for TRPV3 in these areas needs further 
investigation. A functional role for TRPV3 in pain is not yet 
well established. Some studies may point towards this direc-
tion. One study showed an increase in TRPV3 expression 
following brachial plexus avulsion, however, its symptoms 
are not pain related [190]. Another feature of TRPV3 which 
prompts its possible role in pain is its sensitization upon re-
peated heat applications in skin cells and heterologous ex-
pression systems, a phenomenon yet to be confirmed in sen-
sory neurons [32, 141, 166]. An increase in expression was 
also seen in skin cells during breast pain in addition to 
TRPV1 upregulation in nociceptors [68]. A recent study 
showed that TRPV3 in oral and nasal epithelium is activated 
and sensitized by non-selective pungent compounds like 
carvacrol, thymol, eugenol, 6-tert-butyl-m-cresol, dihydro-
carveol, carveol and (+)-borneol [222, 237]. Camphor, men-
thol, 2-APB and diphenylboronic anhydride (DPBA) are the 
other non-selective agonists of TRPV3 which can activate 
and sensitize it to repeated applications [33, 124]. Also 
TRPV3 response to heat is sensitized in the presence or prior 
applications of its chemical agonists [141, 237]. Since cam-
phor and menthol exhibit opposite thermal properties of 
warm and cool sensation, a role for TRPV3 in coding for 
cool sensation is not proven. Such paradoxes need to be re-
solved. TRPV3 pharmacology will also need more than the 
existing two known non-selective antagonists of TRPV3, 
ruthenium red and diphenyltetrahydrofuran (DPTHF) [33]. 
Chemical stimulation of TRPV3 by these non-selective com-
pounds increases the complexity of TRPV3 pharmacology 
and more detailed characterization and physiological role in 
pain models need to be addressed before it can be considered 
a validated target for such therapy. Interestingly, a recent 
study has shown that TRPV3 can be potentiated by arachi-
donic acid and its metabolites, the endogenous mediators of 
inflammatory response in skin cells [81]. The close proxim-
ity of nociceptors to skin epidermal layers, where functional 
TRPV3 is present, makes it a potential molecule with an 
extended role in physiology and pathology of thermosensa-
tion and pain [26, 114]. Such an extended role may involve 
activation of TRPV3 in the skin followed by release of some 
diffusible neuroactive substances like ATP that interact with 
the terminals of the nociceptors. The importance or contribu-
tion of TRPV3 in disease and therapy require further investi-
gations. Development of antagonists for TRPV3 seems bene-
ficial to overcome its sensitization in pain settings. However, 
these agents may have side effects of skins barrier integrity. 
TRPV4 
  Innocuous warm temperatures (27-32
oC) activate the 
thermoTRP TRPV4 (previously coined with several names, 
including VRL-2, OTRPC4, VR-OAC and TRP12). It was 
first identified as an osmoreceptor [71, 117, 201, 228, 235]. 
TRPV4 is reported to have a wide tissue distribution pattern 
and to function in both excitable and non-excitable cells. 
TRPV4 knockout studies have resulted in an intensive ex-
amination of function in physiology and pathology. Here we 
focus on pain mechanisms that have emerged recently. 
Expression, Physiology, Pathology 
  Expression of TRPV4 in the nociceptor class of sensory 
neurons in DRG and trigeminal ganglia earlier limited to 
mRNA studies [71, 117] is now extended to functional pro-
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gesia and allodynia following its sensitization during hypo-
osmotic mediated inflammation, taxol-induced neuropathy or 
mild hypertonic insult [4-6]. These studies have shown that 
PGE2 and PAR2 mediated sensitization of TRPV4 occurs 
during inflammatory hyperalgesia. TRPV4 knockdown stud-
ies have also shown impaired sensitivity to acid, increase in 
mechanical nociceptive threshold with unchanged response 
to heat and touch and reduced thermal hyperalgesia [118, 
202, 214]. However, more studies are necessary to confirm if 
there is a central component to the diminished mechanical 
pain behavioral phenotype observed in TRPV4 knockout 
studies. The CNS expression includes neurons of circumven-
tricular organs, ependymal cells of choroids plexus, cerebral 
cortex, thalamus, hippocampus, and cerebellum [117]. A role 
for TRPV4 in regulating excitability of mouse hippocampal 
neurons at physiological body temperature has recently been 
demonstrated [182]. 
  Numerous studies provide evidence for TRPV4 as being 
a crucial mechano- or osmo-receptor in other cell types, such 
as vascular aortic endothelial cells, blood–brain barrier endo-
thelial cells, renal collecting duct cells, vascular smooth 
muscle cells, hypothalamus (neurons of the circumventricu-
lar organs and the organum vasculosum of the lamina termi-
nalis with projections to the magnocellular regions of the 
supraoptic and paraventricular nuclei) and cochlear hair cells 
[161]. Expression of TRPV4 in keratinocytes and its re-
sponse to warm temperatures has raised the possibility of a 
sensory role of thermoTRP’s in non-neuronal cells [31, 32, 
71]. Aberrant thermal selection in TRPV4 knockout studies 
provided physiological evidence for its role in thermosensa-
tion [114].  
Activation and Regulation 
  In addition to physical stimuli like heat, pressure and 
hypotonicity, chemical activation of TRPV4 include exoge-
nous and endogenous ligands. TRPV4 pharmacology has had 
mixed progress in light of the non-availability of selective 
antagonists. 
Synthetic Phorbol Esters 
 4 -phorbol 12,13-didecanoate (4-PDD) and other non-
active 4 phorbol ester isomers selectively activate TRPV4 
[228, 236] active phorbol esters like PMA, PDD and PDBu 
are agonists of TRPV4 at warmer temperatures and activate 
TRPV4 in a PKC dependent manner [236]. 
Endogenous Second Messenger Metabolites 
  TRPV4 is directly activated by anandamide (AEA) and 
its LOX metabolite arachidonic acid (AA) [229]. Further, 
epoxyeicosatrienoic acid (EET) metabolites of AA formed 
by cytP450 epoxygenase pathway (5,6-EET; 8,9-EET; 11, 
12-EET) also activate TRPV4 [223]. Other endogenous acti-
vators of TRPV4 include N-acyl taurines (NAT’s), which are 
fatty acid amides regulated, by fatty acid amide hydrolase 
(FAAH) [176]. 
Plant Extracts 
  Like other thermoTRP’s activated by natural compounds, 
a very recent study has identified a natural compound bisan-
drographolide A (BAA) contained in extracts of the plant
Andrographis paniculata to activate TRPV4 [192]. 
Intracellular Components as Modulators 
  The presence of intracellular components that interact 
and regulate TRPV4 channel expression and function were 
evident from the fact that it cannot be activated by heat in a 
membrane de-limited condition [228], necessitating the pres-
ence of intracellular components as modulators. A number of 
studies in this direction have emerged. Inhibition of 4
PDD-induced TRPV4 activity was inhibited by an increase 
in both extracellular and intracellular calcium, and this 
modulation was dependent on amino acid residues in the 6
th
transmembrane domain (F707), pore region (D682) and C-
terminus (E797), whereby increased extracellular calcium 
has an inhibitory effect on the channel [230]. Phorbol esters 
and heat activation rely on aromatic residue Tyr-556 at the N 
terminus of transmembrane domain 3 [224] and two hydro-
phobic residues Leu-584 and Trp-586 in the central part of 
transmembrane domain 4 [225]. However, in addition to 
phorbol esters and heat, responses to cell swelling, arachi-
donic acid, and 5,6-EET were affected by mutations of two 
residues Tyr-591 and Arg-594 in the C-terminal part of 
transmembrane domain 4 [225]. These residues of trans-
membrane domains 3 and 4 are thus essential for channel 
gating and ligand binding affinity for TRPV4 [224, 225]. 
Lyn, a member of Src-family of tyrosine kinases, mediated 
tyrosine phosphorylation at Tyr-253 residue to regulate 
TRPV4 response to hypotonic stress [224, 236]. Glycosyla-
tion of TRPV4 at N651 residue of the pore loop region re-
sults in inhibition of membrane trafficking and thus a de-
creased channel response to hypotonicity [238]. Association 
of aquaporin 5 (AQP5) with TRPV4 initiates a regulatory 
volume decrease (RVD) mechanism following hypotonic 
stimulus in epithelial cells [122, 186]. PACSINs, the regula-
tors of synaptic vesicular membrane trafficking and dy-
namin-mediated endocytotic processes, were shown to inter-
act with the amino terminus of TRPV4 and increase plasma
membrane-associated TRPV4 protein. The interaction was 
found between TRPV4-specific proline-rich domain up-
stream of the ankyrin repeats of the channel and the car-
boxyl-terminal Src homology 3 domain of PACSIN 3 [39]. 
A cytoskeletal protein, microfilament-associated protein 
(MAP7), was shown to interact with TRPV4 and form a 
mechanosensitive molecular complex to drive and enhance 
membrane expression of the ion channel [203]. MAP7 inter-
acts with the C-terminus domain between amino acid resi-
dues 789-809. The serine/threoninekinases "With No Lysine 
(K) Kinases" (WNK)1 and WNK4 were also shown to inter-
act with TRPV4 and reduce its cell surface expression, inhib-
iting response to activators like 4 PDD and hypotonicity 
[63].  
  The list of intracellular components that interact with 
TRPV4 may increase in future due to its wide distribution 
and function in various tissues. This will help understand the 
regulatory events controlling TRPV4 in health and disease. 
Therapeutic Potential 
  As pointed out earlier in this section of the review, so far 
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tailed pharmacological characterization in pain conditions 
involving TRPV4. However, such developments are neces-
sary to achieve novel therapeutic strategies for TRPV4-
dependent pain states. TRPV4 knockout studies have how-
ever revealed a physiological role and predicted involvement 
of TRPV4 in diseases like thermal hyperalgesia, neuropathic 
pain, hyperresponsive airway during asthma, hypotonic 
stress during cystic fibrosis, impairment of hearing [152]. In 
parallel to TRPV1, more studies are necessary to elucidate 
sensitization mechanisms of TRPV4 in pain settings when 
exposed to physical stimuli like heat, hypotonic and me-
chanical stress. Given the wide distribution, function and 
complexity in modulation of TRPV4, it would be a challenge 
to target the receptor with agonists or antagonists for specific 
disease states.  
CONCLUSION 
  ThermoTRPs in nociceptors have emerged as potential 
targets for the treatment of pain with a broader perspective. 
Much progress has been made in the last decade since the 
cloning of TRPV1. Clinical trials for TRPV1 as a target for 
selected pain modalities is clear evidence for continuing ef-
forts to search for other thermoTRP transducers of pain in 
nociceptors. Much effort is needed to establish the role of 
thermoTRP’s as potential targets in pain and other therapy 
and the progress so far has been quite rapid. TRPV1 studies 
definitely lead the way to providing the basis for the search 
for remaining thermal transducers of pain in nociceptors. 
Future work on TRPV1 and other thermoTRP’s will enhance 
our understanding of somatosensation in health and disease. 
Availability of animal models especially knockout mice of 
each of the above mentioned thermoTRP’s are vital to rap-
idly advance thermoTRP research. Much effort is warranted 
towards development of more specific drugs (agonists/anta-
gonists) to target each thermoTRP for progress in under-
standing TRP pharmacology.  
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